TTP plc

How do you predict the lifespan of a CGM implant without years of in vivo testing? When Glucotrack sought to improve the longevity and performance of their implantable continuous glucose monitor, they faced the challenge of predicting sensor lifespan without lengthy and costly in vivo testing. The complexity of interacting factors, from glucose and oxygen diffusion to enzyme stability, required a precise, data-driven approach. TTP developed an advanced in silico model, enabling faster design decisions, optimised performance, and confidence in a sensor lifespan exceeding three years. Read the full case study: https://lnkd.in/ezE5q_6b

Are you attending Cambridge Wireless Ltd International Conference? TTP's Riya Sharma is on the organising committee for #CWIC 2025, and will be chairing the 'Emerging Technologies session, taking please at 3.40 - 4.40pm 💡 ℹ️ What the session will discuss: How can emerging technologies like quantum, artificial intelligence, biometrics and blockchain contribute to the resilience and security of today’s societies and organisations? From revolutionising sectors such as healthcare, energy and finance to strengthening cyber security, these innovations will usher in a new era defined by unparalleled advances. However, their counterpoint is that many of these innovations pose new critical risks. This session will feature some of the cutting-edge innovations in this space as we explore how we can make the most of these technologies whilst remaining safe. This year’s theme is “Building Resilience: Future-proofing the Future”, where we will explore the challenges around building technological and business resilience in a rapidly changing world. Hope to see you there! Click here to find out more & register: https://lnkd.in/e9vhr-xT #CWIC2025 #Resilience #Security #Conference

Attending World Electrolysis Congress? Join TTP’s Charles Cooke as he presents "Gaming the Odds with First Of A Kind (FOAK) Power-to-X Projects" 📅 Tuesday, 12th February ⏰ 15:30 📍 Stream B, Main congress In this session, Charles will discuss: · FOAK projects are reducing levelised costs by overcoming technical constraints · But, FOAK means higher risks in addition to higher rewards · How do we increase reward whilst reducing exposure to risk in FOAK projects? Meet Charles Cooke & Tim Lackie at Stand 24 to discuss how we can work together to accelerate the energy transition by developing pioneering power-to-X technologies 🌍 Hope to see you there! #WorldElectrolysisCongress #PowerToX #Innovation World Hydrogen Leaders

🔎 UTI Diagnostics: A Critical Step Toward Better Women's Health and Antimicrobial Stewardship 🔎 Urinary tract infections (UTIs) are one of the most frequently diagnosed infections, yet their management often relies on imprecise, outdated diagnostic methods. This can lead to misuse of antibiotics, rising antimicrobial resistance (AMR), and unnecessary patient suffering. The good news? Advancements in diagnostic technology are opening doors to: ✅ Faster and more accurate UTI detection ✅ Reduced over-prescription of antibiotics ✅ Improved patient outcomes and quality of care As healthcare providers and innovators, it's time to embrace solutions that can drive meaningful change in UTI management—enhancing clinical decision-making, protecting antibiotics, and empowering women’s health. 🚀 Let’s take action now. Read our latest article to explore how cutting-edge diagnostic solutions can reshape the future of UTI care and antimicrobial stewardship. 📖 Read it here: https://lnkd.in/e_SC2Nz5 What do you think is the biggest challenge in improving UTI diagnosis today? Share your thoughts below! 👇 #HealthcareInnovation #UTIDiagnostics #AntimicrobialStewardship #WomensHealth #MedTech #Diagnostics #PatientCare

Come meet the TTP Neurotech team in Orlando at #NANS2025. Hannah Claridge, Alon Greenenko and Alex Stokoe will be on booth #110 with 'Bill' demonstrating how TTP enables efficient implant charging systems with patients + surgeons in mind. You can also find out about our in-house design and manufacturing capabilities for thin film electrode technologies. We look forward to talking about how we can help accelerate your next neurotechnology product development. #NANS #Neuromodulation #Neurotechnology #AIMD

The world of cell and gene therapy is complex and evolving. Can generative AI really help accelerate breakthroughs? While AI's role in drug discovery is well-known, its application in therapy development is only just beginning. According to McKinsey, AI could generate $100 billion for pharma and medical product companies—but how can therapy developers take advantage today? In the latest episode of Invent: Life Sciences, Stuart Lowe is joined by industry leaders: 👥 Kenneth Harris, Chief Strategy Officer & Head of AI, OmniaBio 👥 Sean Bedingfield PhD, PhD, Senior Advisor, Eli Lilly and Company Together, they explore: 🔍 How AI is currently being used in therapy R&D 🔍 Barriers to adoption in such a regulated space 🔍 The future outlook for AI-driven innovations 🎧 Don’t miss this conversation—listen now: https://lnkd.in/egVqbhsW #LifeSciences #AIinPharma #Biotech #Innovation #CellAndGeneTherapy #DigitalHealth

Join Wenshu Xu, Jonathan Wingfield and Greg Walkowiak at the SLAS (Society for Laboratory Automation and Screening) International Conference this week in San Diego, USA. They'll be around to discuss: How bespoke, innovative, and sustainable tools such as high-throughput screening, microfluidics, and organoids can transform drug discovery workflows. Accelerating the Design-Make-Test-Analyse cycle with bespoke lab automation solutions, creating faster, more efficient pathways to clinical trials. Collaborating to develop scalable, sustainable, and future-proof technologies that empower biotech and pharmaceutical innovators to deliver life-changing medicines. Find out more about how we can help you and book a meeting here - https://lnkd.in/e3e_NVu2 #SAS2025

"🚀 AI’s Game-Changing Role in Cell & Gene Therapy Generative AI is revolutionising industries, but how is it transforming cell and gene therapy development? In Episode 4 of the Invent: Life Sciences podcast, host Stuart Lowe is joined by: 🧬 Kenneth Harris, Chief Strategy Officer and Head of AI at OmniaBio 🧬 Sean Bedingfield PhD, PhD, Senior Advisor at Eli Lilly and Company Together, they explore how AI is moving from promise to practice, covering: ✅ The current impact of AI in therapy development ✅ Challenges and opportunities for cell and gene therapy ✅ How AI could unlock $100 billion in economic value, as projected by McKinsey & Company 🎧 Tune in to discover how AI is shaping the future of medicine: https://lnkd.in/gmDNdVaV #AI #Pharma #CellAndGeneTherapy #LifeSciences #HealthcareInnovation #GenerativeAI"

🚨 UTIs: A Global Health Challenge with a Diagnostic Opportunity 🚨 Did you know that urinary tract infections (UTIs) are one of the most common bacterial infections worldwide, affecting over 50% of women at least once in their lifetime? Despite their prevalence, UTI diagnosis often relies on outdated methods, leading to misdiagnosis, overuse of antibiotics, and increasing antimicrobial resistance (AMR). In our latest article, we explore how advancements in UTI diagnostics present a unique opportunity to: 🔬 Enhance diagnostic accuracy – ensuring the right treatment is prescribed, reducing unnecessary antibiotic use. 💊 Improve antimicrobial stewardship – a crucial step in combating rising AMR threats. 👩⚕️ Transform women's health – by addressing the persistent gaps in UTI management and care. With innovation in diagnostic technology, we can empower healthcare providers to make data-driven decisions and provide better patient outcomes. Curious about the future of UTI diagnostics? Read the full article to learn how emerging solutions can make a real impact: 👉 https://lnkd.in/eSVruUJv Let’s start a conversation – how do you see diagnostic innovation shaping the future of UTI treatment? #HealthcareInnovation #AntimicrobialStewardship #WomensHealth #UTIDiagnostics #MedTech #Diagnostics

Accelerating the development of cell and gene therapies – the ‘why’ and the ‘how’" With the cell and gene therapy industry at a pivotal crossroads, one key question looms large: will these groundbreaking therapies become mass-market cures, or will they remain accessible to only a select few? Stuart explored how patient needs can – and should – shape development decisions well before therapies reach the clinic. Therapy developers today must strike a delicate balance between demonstrating short-term clinical progress and preparing for large-scale commercialisation. One powerful solution? Early adoption of process automation. By integrating automation early in development, therapy developers can: ✅ Reduce handling variability ✅ Improve facility utilisation ✅ Accelerate transfer to commercial manufacturing In his talk, Stuart Lowe highlighted how TTP is partnering with companies to implement targeted process automation, using a systematic approach that: 🔹 Focuses on optimising individual process steps 🔹 Identifies the right off-the-shelf or custom hardware 🔹 Aligns scalability with process development goals A huge thank you to everyone who attended and engaged with Stuart’s session. If you’re interested in learning more about how process automation can accelerate your cell and gene therapy development, feel free to reach out! #ATW25 #AdvancedTherapies #CellAndGeneTherapy